global-women-health-orthopedics-congress-2018-tracks

5 / 6

Page 25
S e p t e m b e r 0 6 - 0 7 , 2 0 1 8 | B a n g k o k , T h a i l a n d
alliedacademies Joint Event on
Global Women Health 2018 & Orthopedics Congress 2018 Archives of General Internal Medicine | ISSN: 2591-7951 | Volume 2
BREAST CANCER, GYNECOLOGY AND WOMEN HEALTH
ORTHOPEDICS AND RHEUMATOLOGY
&
World Congress on
Annual Conference on
Wassil Nowicky, Arch Gen Intern Med 2018, Volume 2 | DOI: 10.4066/2591-7951-C3-008
THE EFFECT OF ANTI-CANCER
PREPARATION WITH A SELECTIVE EFFECT
UKRAIN (NSC 631570) ON WOMEN
REPRODUCTIVE CANCERS
Wassil Nowicky
Nowicky Pharma, Austria
First indications on the selective effect of NSC‐631570 on the cancer cells
were provided in an early study when different oxygen consumption by
normal liver cells and Ehrlich’s tumor ascitic cells after the incubation with
NSC‐631570 was re-vealed. There was a report on the success-ful using
NSC‐631570 in the treatment of ovarian cancer. Also, in the tests of Na-tional
Cancer Institute NSC‐631570 was toxic against all ovarian cancer cell lines
tested. NSC‐631570 induced apoptosis in a panel of cancer cell lines (ovarial
and cervical cancer HeLa, HeKB, HeKS32, HeBcl3, HeNFR and HeIKK, human
colon cancer SW480, human renal carcinoma HEK293, human osteosarcoma
MG‐63) by activating the caspases of the intrinsic cell death pathway.
Interestingly, non‐transformed fibroblasts (hTERT) cell line was insensitive
to the drug. In the tests on human ovarian and cervix carcinoma cells HeLa,
squamous carcinoma cells WHCO5, normal kidney cell line Graham 293, and
transformed kidney cell line Vero from African green monkey, NSC‐631570
inhibited the tubulin polymerization and caused a metaphase block in cancer
cells which is characterized by abnormal chromosomal distribution, and
results in the formation of micronuclei and in apoptosis.
Recent Publications
1.Wassil Nowicky (2017). Selective and immunomodulating properties of
the anticancer proton preparation on basis of greater celandine alkaloids
NSC631570. J Clin Exp Oncol. DOI: 10.4172/2324-9110-C1-004.
Wassil Nowicky is the Director of Nowicky Pharma
and President of the Ukrainian Anti-Cancer Institute
(Vienna, Austria). He has finished his study at the
Radio-technical Faculty of the Technical University of
Lviv (Ukraine) with the end of 1955. He is invited as
an honorable speaker to take part in many scientific
international congresses and conferences in USA,
Australia, Japan, UAE, Europe. He is the author of over
300 scientific articles dedicat-ed to cancer research.
He is a real Member of the New York Academy of
Sciences, Member of the European Union for applied
immunology and of the American Association for sci-
entific progress, honorary doctor of the Janka Kupala
University in Hrodno, honorary doctor causa of the
Open International University on Complex Medicine in
Colombo, honorary Member of the Austrian Society of
a name od Albert Schweizer.
BIOGRAPHY